SCYX - SCYNEXIS, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Jersey City,
United States
Type: Equity
SCYX price evolution
SCYX
| (in millions $) | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.54 | $36.02 | $34.59 | $44.62 |
| Short term investments | $47.04 | $44.76 | $40.31 | $44 |
| Net receivables | $0.23 | $19.47 | $21.83 | $23.9 |
| Inventory | $13.11 | |||
| Total current assets | $94.58 | $101.67 | $102.12 | $128.64 |
| Long term investments | $10.66 | $13.94 | $23.59 | $17.11 |
| Property, plant & equipment | $2.23 | $2.3 | $2.36 | $2.42 |
| Goodwill & intangible assets | $0.1 | |||
| Total noncurrent assets | $13.23 | $16.58 | $26.3 | $19.91 |
| Total investments | $57.7 | $58.7 | $63.91 | $61.12 |
| Total assets | $107.81 | $118.25 | $128.41 | $148.55 |
| Current liabilities | ||||
| Accounts payable | $5.35 | $8.92 | $7.15 | $3.49 |
| Deferred revenue | $3.05 | $3.19 | $3.92 | $4.08 |
| Short long term debt | $13.16 | $12.75 | $0.34 | $0.33 |
| Total current liabilities | $25.23 | $27.35 | $16.3 | $16.79 |
| Long term debt | $2.39 | $2.49 | $14.74 | $14.48 |
| Total noncurrent liabilities | $22.17 | $16.8 | $39.15 | $39.77 |
| Total debt | $15.54 | $15.23 | $15.08 | $14.81 |
| Total liabilities | $47.4 | $44.15 | $55.45 | $56.55 |
| Shareholders' equity | ||||
| Retained earnings | -$369.29 | -$354.84 | -$355.25 | -$335.66 |
| Other shareholder equity | ||||
| Total shareholder equity | $60.41 | $74.11 | $72.96 | $91.99 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.59 | $46.03 | $104.7 | $93.31 |
| Short term investments | $40.31 | $27.69 | ||
| Net receivables | $21.83 | $2.1 | $0.86 | $2.9 |
| Inventory | $0.9 | $0.46 | ||
| Total current assets | $102.12 | $79.06 | $109.38 | $98.21 |
| Long term investments | $23.59 | |||
| Property, plant & equipment | $2.36 | $2.59 | $2.91 | $3.3 |
| Goodwill & intangible assets | $0.41 | $1.06 | ||
| Total noncurrent assets | $26.3 | $8.75 | $10.46 | $4.33 |
| Total investments | $63.91 | $27.69 | ||
| Total assets | $128.41 | $87.81 | $119.84 | $102.54 |
| Current liabilities | ||||
| Accounts payable | $7.15 | $5.94 | $7.85 | $4.64 |
| Deferred revenue | $3.92 | |||
| Short long term debt | $0.34 | $0.28 | $0.07 | $0.05 |
| Total current liabilities | $16.3 | $17.62 | $13.62 | $26.4 |
| Long term debt | $14.74 | $45.39 | $43.56 | $19.79 |
| Total noncurrent liabilities | $39.15 | $66.96 | $64.96 | $53.38 |
| Total debt | $15.08 | $48.6 | $43.63 | $19.84 |
| Total liabilities | $55.45 | $84.58 | $78.58 | $79.78 |
| Shareholders' equity | ||||
| Retained earnings | -$355.25 | -$422.29 | -$359.48 | -$326.61 |
| Other shareholder equity | ||||
| Total shareholder equity | $72.96 | $3.23 | $41.26 | $22.76 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.74 | $1.37 | $5.8 | |
| Cost of revenue | $14.68 | |||
| Gross Profit | $0.74 | $1.37 | -$8.89 | |
| Operating activities | ||||
| Research & development | $6.81 | $7.21 | $10.59 | |
| Selling, general & administrative | $3.17 | $3.67 | $3.59 | |
| Total operating expenses | $9.97 | $10.88 | $14.18 | |
| Operating income | -$9.24 | -$9.51 | -$23.07 | |
| Income from continuing operations | ||||
| EBIT | -$14.26 | $1.15 | -$19.23 | |
| Income tax expense | $0.53 | $0.14 | ||
| Interest expense | $0.2 | $0.2 | $0.22 | |
| Net income | ||||
| Net income | -$14.46 | $0.41 | -$19.59 | |
| Income (for common shares) | -$14.46 | $0.41 | -$19.59 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $140.14 | $5.09 | $13.16 | |
| Cost of revenue | $15.62 | $0.63 | $0.31 | |
| Gross Profit | $124.52 | $4.46 | $12.85 | |
| Operating activities | ||||
| Research & development | $30.93 | $27.26 | $23.77 | $36.52 |
| Selling, general & administrative | $20.92 | $62.96 | $49.92 | $14.63 |
| Total operating expenses | $51.85 | $90.22 | $73.69 | $51.15 |
| Operating income | $72.67 | -$85.76 | -$60.84 | -$51.15 |
| Income from continuing operations | ||||
| EBIT | $70.31 | -$62.31 | -$33.29 | -$57.15 |
| Income tax expense | $0.14 | -$4.7 | -$3.09 | -$3.15 |
| Interest expense | $3.13 | $5.2 | $2.66 | $1.18 |
| Net income | ||||
| Net income | $67.04 | -$62.81 | -$32.87 | -$55.19 |
| Income (for common shares) | $67.04 | -$62.81 | -$32.87 | -$55.19 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$14.46 | $0.41 | -$19.59 | -$1.76 |
| Operating activities | ||||
| Depreciation | $0.13 | $0.15 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.76 | $0.7 | $0.56 | $0.63 |
| Total cash flows from operations | -$10.86 | -$4.01 | -$7.74 | $12.42 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $1.37 | $5.45 | -$2.15 | -$26.34 |
| Total cash flows from investing | $1.37 | $5.45 | -$2.15 | -$26.34 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.03 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$0.01 | -$0.14 | $0.03 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.49 | $1.43 | -$10.02 | -$13.89 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $67.04 | -$62.81 | -$32.87 | -$55.19 |
| Operating activities | ||||
| Depreciation | $0.58 | $0.61 | $0.38 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.62 | $3.69 | $2.09 | $2.22 |
| Total cash flows from operations | $60.16 | -$79.88 | -$54.56 | -$49.35 |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | -$34.88 | -$27.38 | $6.48 | |
| Total cash flows from investing | -$34.88 | -$27.39 | -$1.17 | $6.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.06 | $47.27 | $38.58 | $90.37 |
| Net borrowings | -$36.65 | $4.97 | $28.75 | $9.51 |
| Total cash flows from financing | -$36.72 | $48.6 | $67.12 | $94 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.44 | -$58.67 | $11.39 | $51.12 |
News
Fundamentals
| Market cap | $46.94M |
|---|---|
| Enterprise value | $35.95M |
| Shares outstanding | 37.86M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.78 |
| Book/Share | 1.60 |
| Cash/Share | 0.70 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.76 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.75 |
| Quick ratio | 3.75 |